Experimental evidence published by Han et al. shows an increased CD73 expression in NSCLC patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK)-rearrangements. This evidence concerns the gene EGFR and non-small cell lung carcinoma.